$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

IDEXX Laboratories posted a strong Q2 2025 beat with significant margin expansion, raised full-year guidance, and highlighted robust international recurring revenue growth, supporting its premium valuation.

# IDEXX Laboratories Delivers Robust Q2 2025 Beat with Margin Expansion and Upgraded Guidance

---

## Executive Summary

- **IDEXX Laboratories (IDXX) delivered a standout Q2 2025, beating on both top and bottom lines**: Adjusted EPS of **$3.50** (up 17% YoY, vs. $3.28 consensus) and revenue of **$1.11 billion** (vs. $1.06 billion consensus).  
- **Earnings quality was high**, with gross margin rising to **62.6%** (up 90 bps YoY) and operating margin expanding sharply to **33.6%** (up 730 bps YoY), driven by disciplined cost management and strong recurring revenue growth, especially in the CAG diagnostics segment.
- **Management’s tone was bullish**, raising full-year guidance for both EPS and revenue well above Street expectations, citing robust international growth and sustained demand in core diagnostics.
- **Key upside not fully reflected in the market** includes the accelerating international recurring revenue and the long-term benefits of ongoing productivity initiatives. Risks remain around the sustainability of margin gains and potential regulatory or competitive headwinds.
- **Catalyst watch:** Continued international expansion, further margin improvement, and Q3 2025 results will be key for sustaining the current positive momentum.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise | YoY Change |
|----------------|------------|-----------|----------|------------|
| Revenue        | $1.11B     | $1.06B    | +$50M    | +N/A       |
| Adjusted EPS   | $3.50      | $3.28     | +$0.22   | +17%       |
| Gross Margin   | 62.6%      | —         | —        | +90 bps    |
| Operating Margin| 33.6%     | —         | —        | +730 bps   |
| CAG Recurring Revenue Growth | 11% (organic) | — | — | +N/A      |
| International Recurring Revenue Growth | 15% (reported), 11% (organic) | — | — | +N/A |

---

## Earnings Quality

IDEXX Laboratories’ Q2 2025 results reflect **high-quality earnings**. Revenue growth was driven by robust organic volume increases, particularly in the CAG diagnostics segment, with both U.S. and international markets contributing. The **improved revenue mix**—with a higher share of recurring diagnostics revenue—supported margin expansion. **Operating expenses fell 9% YoY**, reflecting effective cost discipline and productivity initiatives. The divergence between strong sales growth and even stronger margin expansion highlights the company’s ability to leverage scale and control costs, resulting in significant operating leverage.

---

## Management Commentary & Guidance

Management’s tone on the call was **confident and optimistic**. They raised full-year 2025 guidance for both EPS (**$12.40–$12.76**, up from prior) and revenue (**$4.21–$4.28 billion**), both well above consensus. The guidance assumes continued strength in recurring revenue, especially in diagnostics, and further international expansion. Management emphasized the sustainability of current momentum, citing solid demand, improved execution, and ongoing cost discipline.

---

## Key Risks

- **Margin sustainability:** Reliance on cost-saving measures and operating leverage may face headwinds if one-off benefits normalize or if inflationary pressures return.
- **Regulatory and competitive risks:** Any adverse regulatory developments or increased competition could pressure future growth and margins.
- **Demand-side risks:** A slowdown in veterinary or diagnostics spending could impact recurring revenue streams.

---

## Expected Market Reaction

The stock rallied strongly post-earnings, reflecting **positive investor sentiment** around the earnings beat, margin expansion, and upgraded guidance. Analysts are likely to further raise estimates and price targets, with the premium valuation seen as justified by consistent execution and growth. However, the market may be underestimating the durability of international recurring revenue growth and the compounding benefits of ongoing productivity initiatives.

---

## Final Takeaway

**IDEXX Laboratories delivered a strong, high-quality quarter, with clear beats on all key metrics and a bullish outlook.** The market appears to be underappreciating the speed and scale of international recurring revenue growth and the sustainability of margin improvements. Risks remain around the durability of cost savings and potential regulatory headwinds, but the company’s execution and guidance upgrades support the current premium valuation.

**Upcoming catalysts:**  
- Q3 2025 earnings (to confirm momentum and margin trends)  
- Updates on international expansion and recurring revenue growth

IDEXX Laboratories remains well-positioned for continued outperformance, with disciplined cost management and robust demand underpinning its growth trajectory.

IDEXX (IDXX) Q2 Beat: Margin Expansion & Upgraded Outlook

Conagra Brands faces ongoing margin and volume pressures in Q1 FY26, but portfolio optimization and cost-saving initiatives could offer underappreciated upside amid persistent inflation.

# Conagra Brands Q1 FY26 Earnings Outlook: Navigating Margin Pressures and Portfolio Realignment Amid Persistent Inflation

## Executive Summary

We maintain a **Neutral** outlook for Conagra Brands (NYSE: CAG) heading into Q1 FY26, as persistent cost inflation and softening volumes are likely to weigh on near-term results. **Q4 FY25 revenue declined 4.3% YoY to $2.78B**, with adjusted gross margin compressing by 184 bps to 25.8%. Management’s cautious tone and lack of explicit Q1 guidance reinforce expectations for continued margin and volume headwinds. However, the market may be underestimating the potential for **portfolio optimization and cost-saving initiatives** to provide incremental support to margins and cash flow, especially as divestitures free up capital for higher-growth segments.

## Recent Trends Signal What’s Next

Recent quarters have shown a clear deceleration in top-line growth and margin resilience. **Q4 FY25 revenue fell to $2.781B (–4.3% YoY)**, with gross margin at **25.8%** (down 184 bps YoY) and EPS at **$0.55**. Volume declined **2.5% YoY**, and price/mix slipped **1.0%**. Segment-level softness was most acute in Refrigerated & Frozen (–4.4% YoY) and International (–13.8% YoY). These trends suggest Q1 FY26 will likely see continued revenue and margin pressure, especially if cost inflation and FX headwinds persist.

### Quarterly Financial Trend Table

| Quarter    | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | EPS   |
|------------|--------------|------------------|----------------------|----------------|-------|
| Q3 FY25    | 2.86         | 26.2             | 14.1                 | 8.7            | 0.58  |
| Q4 FY25    | 2.78         | 25.8             | 13.7                 | 8.3            | 0.55  |
| Q1 FY26E   | 2.75         | 25.8             | 13.5                 | 8.2            | 0.55  |
| Q2 FY26E   | 2.77         | 25.9             | 13.6                 | 8.3            | 0.56  |

*Trend: Revenue and margins have trended lower over the last two quarters, with little sign of near-term recovery.*

## Management’s Forward Tone and Positioning

Management’s recent commentary has been **notably cautious**, emphasizing ongoing macro and cost headwinds. In the Q4 FY25 call, CEO Sean Connolly stated, **“We continue to face elevated inflation and macroeconomic uncertainty, which is pressuring both volume and margin.”** This is a marked shift from the more optimistic tone in late FY25, where management highlighted “early signs of normalization in demand.” The current focus is on **cost savings and portfolio reshaping**, with explicit FY26 guidance for **adjusted EPS of $1.70–$1.85** and **organic net sales growth of –1% to +1%**. The absence of Q1-specific guidance and the defensive language suggest management is bracing for a challenging start to the fiscal year.

## KPI Trends & Upcoming Quarter Drivers

The most relevant KPIs for Q1 FY26 are **volume growth, price/mix, and inventory levels**. In Q4 FY25, **volume declined 2.5% YoY**, price/mix fell **1.0%**, and inventory ended at **$2.048B** (up YoY). These trends point to continued pressure on revenue and margin, as slower sell-through and elevated inventory could lead to higher discounting or write-downs. Management’s focus on cost control is critical, but with **COGS inflation running at ~7%** and new tariffs adding ~3% to COGS, the ability to offset these pressures will be tested.

### KPI Movement Table

| KPI                | Q4 FY24 | Q1 FY25 | Q4 FY25 | Q1 FY26E | YoY Change | QoQ Change |
|--------------------|---------|---------|---------|----------|------------|------------|
| Volume Growth (%)  | –1.8    | –2.0    | –2.5    | –2.3     | –0.5       | +0.2       |
| Price/Mix (%)      | +0.5    | –0.2    | –1.0    | –0.8     | –1.3       | +0.2       |
| Inventory ($B)     | 1.95    | 2.01    | 2.05    | 2.08     | +0.13      | +0.03      |

*Trend: Volume and price/mix remain negative, while inventory continues to build, signaling ongoing demand softness and margin risk.*

## Missed by the Street

A key overlooked signal is the **potential for margin improvement from portfolio optimization**. Recent filings highlight the divestiture of Van de Kamp’s and Mrs. Paul’s frozen seafood brands, with management stating, **“We are investing in our high-potential frozen and snacks domains.”** (Q4 FY25 10-K). This strategic shift could drive a more favorable margin mix and operational focus, but the upside is not yet reflected in consensus estimates. Additionally, the **footnote disclosure of incremental supply chain automation investments** suggests a medium-term cost tailwind that is underappreciated.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($B) | EPS   | Gross Margin (%) | Key Assumptions                                                                 |
|----------|--------------|-------|------------------|---------------------------------------------------------------------------------|
| Bull     | 2.80         | 0.60  | 26.0             | Cost savings materialize, FX/tariff headwinds ease, volume stabilizes            |
| Base     | 2.75         | 0.55  | 25.8             | Continued inflation and volume softness, partial offset from cost initiatives    |
| Bear     | 2.70         | 0.50  | 25.5             | Worsening volume declines, persistent cost/FX pressures, limited pricing power   |

**Base case is most likely**, given current evidence of ongoing cost inflation, soft demand, and management’s defensive posture. Upside could emerge if cost savings and portfolio actions deliver faster-than-expected benefits.

## Appendix – Data Tables & Management Quotes

### Quarterly Financials Table

| Quarter    | Revenue ($B) | EPS   | Gross Margin (%) | Operating Margin (%) |
|------------|--------------|-------|------------------|----------------------|
| Q3 FY25    | 2.86         | 0.58  | 26.2             | 14.1                 |
| Q4 FY25    | 2.78         | 0.55  | 25.8             | 13.7                 |
| Q1 FY26E   | 2.75         | 0.55  | 25.8             | 13.5                 |
| Q2 FY26E   | 2.77         | 0.56  | 25.9             | 13.6                 |

### KPI Movement Table

| KPI                | Q4 FY24 | Q1 FY25 | Q4 FY25 | Q1 FY26E |
|--------------------|---------|---------|---------|----------|
| Volume Growth (%)  | –1.8    | –2.0    | –2.5    | –2.3     |
| Price/Mix (%)      | +0.5    | –0.2    | –1.0    | –0.8     |
| Inventory ($B)     | 1.95    | 2.01    | 2.05    | 2.08     |

### Key Management Quotes

1. **“We continue to face elevated inflation and macroeconomic uncertainty, which is pressuring both volume and margin.”**  
   *Q4 FY25 Earnings Call*  
   *Signals ongoing headwinds and a defensive outlook for Q1.*

2. **“Our cost-saving initiatives are on track, but input cost inflation remains a significant challenge.”**  
   *Q4 FY25 Earnings Call*  
   *Implies that cost actions may only partially offset inflationary pressures.*

3. **“We are investing in our high-potential frozen and snacks domains.”**  
   *Q4 FY25 10-K*  
   *Highlights a strategic shift toward higher-margin categories.*

4. **“The sale of our frozen seafood brands will allow us to focus on core growth areas and reduce debt.”**  
   *Q4 FY25 Press Release*  
   *Suggests improved capital allocation and operational focus.*

5. **“We expect COGS inflation of approximately 7% in the coming quarter, with tariffs adding incremental pressure.”**  
   *Q4 FY25 Earnings Call*  
   *Quantifies the cost headwind for Q1 FY26.*

6. **“We are not providing explicit Q1 guidance at this time due to ongoing market volatility.”**  
   *Q4 FY25 Earnings Call*  
   *Reinforces management’s cautious stance and limited visibility.*

7. **“Supply chain automation investments are expected to yield cost benefits over the next several quarters.”**  
   *Q4 FY25 10-K Footnote*  
   *Points to a potential medium-term margin tailwind not yet in consensus.*

---

**Bottom Line:**  
Conagra Brands enters Q1 FY26 with persistent margin and volume headwinds, but cost-saving and portfolio optimization efforts could provide incremental support. Investors should closely monitor volume trends, margin execution, and the pace of asset optimization for early signs of a turnaround.

Conagra (CAG): Margin Pressures vs. Portfolio Upside